Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
October 23, 2018 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
October 05, 2018 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 18, 2018 08:00 ET
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...
Naturopathic Doctors Offer Botanical Medicine to Manage Cold and Flu
September 05, 2018 12:00 ET
|
Institute for Natural Medicine
Seattle, Sept. 05, 2018 (GLOBE NEWSWIRE) -- As new research uncovers that nearly one third of antibiotic prescriptions are not needed and not effective, more people are seeking out non-drug...
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
August 14, 2018 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
August 09, 2018 16:05 ET
|
Iterum Therapeutics plc
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...
Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa
March 02, 2018 11:55 ET
|
Otonomy, Inc.
SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
Otonomy Announces Plan to Focus Resources on Development Programs
November 27, 2017 16:30 ET
|
Otonomy, Inc.
Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...